Advances in medicinal chemistry, genomics and proteomics have culminated in the discovery of a vast array of candidate drugs, namely bioactive small molecules, proteins and peptides. Many of these are already marketed for the treatment of a variety of diseases. Hundreds of others are undergoing clinical trials. There is, however, a need to improve such drugs as their effective use is often compromised by limitations inherent in their molecular structure.
Multi-objective design of drug molecules so as to promote efficacy, favourable pharmacokinetics and reduced toxicity is a challenge early in the drug discovery process. In the case of proteins and peptides, a number of approaches have been proposed for their delivery in ways that protect them from the vagaries of the biological milieu. They include subtle changes in their amino acid sequence, fusion with proteins, glycosylation, conjugation with polymers, and entrapment into nanoparticles, all leading to improved drug pharmacokinetics and pharmacodynamics.
Drug discovery through molecular design and advanced drug delivery are the vanguard of modern therapeutics. They are the subject of this international Congress. It is the task of the Hellenic Pharmaceutical Society, the Hellenic Society of Medicinal Chemistry and the International Liposome Society to promote both.
The organisers look forward to your participation and support.
Professor Gregory Gregoriadis